866-997-4948(US-Canada Toll Free)

Synovial Sarcoma - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 189 Pages

Synovial Sarcoma - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Pipeline Review, H2 2017, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.

Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 7, 3 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Synovial Sarcoma - Overview 6
Synovial Sarcoma - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 12
Synovial Sarcoma - Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Synovial Sarcoma - Companies Involved in Therapeutics Development 21
Adaptimmune Therapeutics Plc 21
Advenchen Laboratories LLC 21
EpiZyme Inc 22
Immune Design Corp 22
Immunocore Ltd 23
Johnson & Johnson 23
Karyopharm Therapeutics Inc 24
Merck & Co Inc 24
Millennium Pharmaceuticals Inc 25
Novartis AG 25
Pfizer Inc 26
Takara Bio Inc 26
Synovial Sarcoma - Drug Profiles 27
ACXT-3102 - Drug Profile 27
AL-3818 - Drug Profile 28
axitinib - Drug Profile 31
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 37
CMB-305 - Drug Profile 38
CUE-102 - Drug Profile 42
everolimus - Drug Profile 43
Fusion Protein for Oncology - Drug Profile 55
GSK-3377794 - Drug Profile 56
pembrolizumab - Drug Profile 66
quisinostat hydrochloride - Drug Profile 127
sapanisertib - Drug Profile 129
selinexor - Drug Profile 133
SSTC-104 - Drug Profile 155
tazemetostat - Drug Profile 156
TBI-1301 - Drug Profile 167
Synovial Sarcoma - Dormant Projects 168
Synovial Sarcoma - Discontinued Products 169
Synovial Sarcoma - Product Development Milestones 170
Featured News & Press Releases 170
Appendix 187
Methodology 187
Coverage 187
Secondary Research 187
Primary Research 187
Expert Panel Validation 187
Contact Us 187
Disclaimer 188

List of Tables
Number of Products under Development for Synovial Sarcoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Synovial Sarcoma - Pipeline by Adaptimmune Therapeutics Plc, H2 2017
Synovial Sarcoma - Pipeline by Advenchen Laboratories LLC, H2 2017
Synovial Sarcoma - Pipeline by EpiZyme Inc, H2 2017
Synovial Sarcoma - Pipeline by Immune Design Corp, H2 2017
Synovial Sarcoma - Pipeline by Immunocore Ltd, H2 2017
Synovial Sarcoma - Pipeline by Johnson & Johnson, H2 2017
Synovial Sarcoma - Pipeline by Karyopharm Therapeutics Inc, H2 2017
Synovial Sarcoma - Pipeline by Merck & Co Inc, H2 2017
Synovial Sarcoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Synovial Sarcoma - Pipeline by Novartis AG, H2 2017
Synovial Sarcoma - Pipeline by Pfizer Inc, H2 2017
Synovial Sarcoma - Pipeline by Takara Bio Inc, H2 2017
Synovial Sarcoma - Dormant Projects, H2 2017
Synovial Sarcoma - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Synovial Sarcoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *